Antiviral medications for COVID-19
Pro Research Analysisby 
Searched over 200M research papers
Antiviral Medications for COVID-19: Key Drug Classes and Mechanisms
Antiviral medications for COVID-19 target different stages of the SARS-CoV-2 virus life cycle. The main classes include direct-acting antivirals (DAAs), monoclonal antibodies, and host-directed therapies. DAAs inhibit viral replication by targeting viral enzymes such as RNA-dependent RNA polymerase and proteases, while monoclonal antibodies block viral entry by targeting the spike protein. Host-directed therapies aim to modulate the immune response, especially in severe cases Ng2022Gudima2023Singh2022+1 MORE.
Approved and Authorized Antiviral Drugs for COVID-19
Remdesivir
Remdesivir, a nucleotide analog, was the first antiviral to receive FDA Emergency Use Authorization (EUA) for COVID-19. It works by inhibiting the viral RNA polymerase, reducing the time to recovery in hospitalized patients, especially when given early in the disease course. However, its effect on mortality is inconsistent across studies, and it requires intravenous administration, limiting its use to hospital settings Ng2022Singh2022Vegivinti2022+1 MORE.
Paxlovid (Nirmatrelvir + Ritonavir)
Paxlovid is an oral protease inhibitor combination that has shown high efficacy in preventing progression to severe disease, hospitalization, and death when administered early. It is especially beneficial for patients at risk of severe COVID-19 and is easy to administer outside the hospital Ng2022Singh2022Wen2022.
Molnupiravir
Molnupiravir is another oral antiviral that acts as a nucleoside analog, introducing errors into the viral RNA and inhibiting replication. Clinical trials show it reduces hospitalization and mortality rates in mild to moderate COVID-19 cases, with a favorable safety profile Singh2022Wen2022Tian2022.
Monoclonal Antibodies
Several monoclonal antibodies, such as bamlanivimab, casirivimab/imdevimab, and sotrovimab, have been authorized for early treatment of COVID-19. They are effective in reducing symptoms and hospitalization rates by neutralizing the virus, but their efficacy can be reduced by emerging variants like Omicron Ng2022Gudima2023Singh2022.
Other Investigated Antivirals
Other drugs, including favipiravir, sofosbuvir/daclatasvir, lopinavir/ritonavir, and umifenovir, have been tested, but results are mixed or less promising compared to the main approved antivirals. Some, like hydroxychloroquine and ivermectin, showed initial in vitro activity but failed to demonstrate clinical benefit in large trials Yavuz2020Teoh2020Vegivinti2022+1 MORE.
Efficacy and Timing of Antiviral Therapy
Antivirals are most effective when administered early in the course of infection, before the virus reaches peak replication. Early use can prevent progression to severe disease and reduce hospitalization rates. However, no antiviral has consistently demonstrated a reduction in overall mortality in large randomized controlled trials Singh2022Vegivinti2022Wen2022.
Safety and Resistance Considerations
The main approved oral antivirals (Paxlovid, molnupiravir) have shown good safety profiles in clinical trials, with no significant increase in adverse events compared to placebo. However, the potential for resistance, especially with widespread use and emerging variants, remains a concern. Combination therapies may help reduce the risk of resistance Ng2022Singh2022Wen2022.
Future Directions and Ongoing Research
Research continues into new antiviral agents, including antiviral peptides and antisense oligonucleotides, as well as combination therapies to address resistance and improve outcomes. There is also a focus on developing broad-spectrum antivirals and improving access to effective treatments globally Gudima2023Mahendran2020Singh2022+1 MORE.
Conclusion
Antiviral medications such as remdesivir, Paxlovid, and molnupiravir have improved clinical outcomes for COVID-19, especially when used early in the disease. Oral antivirals offer practical advantages for outpatient treatment. While these drugs reduce hospitalization and progression to severe disease, their impact on mortality is limited, and ongoing research is needed to develop new therapies and address emerging variants.
Sources and full results
Most relevant research papers on this topic